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Health  care  cost
Abstract
Introduction:  The  MINERVA  trial  established  that  atrial  preventive  pacing  and  atrial  anti-
tachycardia pacing  (DDDRP)  in  combination  with  managed  ventricular  pacing  (MVP)  reduces
progression  to  permanent  atrial  fibrillation  (AF)  in  patients  with  paroxysmal  or  persistent  AF
and  bradycardia  who  need  cardiac  pacing,  compared  to  standard  dual-chamber  pacing  (DDDR).
It  was  shown  that  AF-related  health  care  utilization  was  significantly  lower  in  the  DDDRP  +  MVP
group  than  in  the  control  group.  Cost  analysis  demonstrated  significant  savings  related  to  this
new  algorithm,  based  on  health  care  costs  from  the  USA,  Italy,  Spain  and  the  UK.
Objective: To  calculate  the  savings  associated  with  reduced  health  care  utilization  due  to
enhanced pacing  modalities  in  the  Portuguese  setting.
Methods:  The  impact  on  costs  was  estimated  based  on  tariffs  for  AF-related  hospitalizationspartment  and  outpatient  visits  in  Portugal.
showed  a  42%  reduction  in  AF-related  health  care  utilization  thanks
ortugal,  this  represents  a  potential  cost  saving  of  2323  euros  per
r  and  17  118  euros  over  a  10-year  period.  Considering  the  number  ofand costs  for  emergency  de
Results: The  MINERVA  trial  
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patients  who  could  benefit  from  this  new  algorithm,  Portugal  could  save  a  total  of  75  369  euros
per  year  and  555  410  euros  over  10  years.  Additional  savings  could  accrue  if  heart  failure  and
stroke  hospitalizations  were  considered.
Conclusion:  The  combination  of  atrial  preventive  pacing,  atrial  antitachycardia  pacing  and  an
algorithm to  minimize  the  detrimental  effect  of  right  ventricular  pacing  reduces  recurrent  and
permanent  AF.  The  new  DDDRP  +  MVP  pacing  mode  could  contribute  to  significant  costs  savings
in  the  Portuguese  health  care  setting.
©  2018  Sociedade  Portuguesa  de  Cardiologia.  Published  by  Elsevier  España,  S.L.U.  This  is  an





Algoritmos  de  pacing;
Custos de  saúde
Análise  de  redução  de  custos  por  utilização  de  novos  algoritmos  de  pacing  em
doentes  com  bradicardia:  estudo  de  caso  português  com  os  resultados  do  estudo
MINERVA
Resumo
Introdução:  Observamos  no  estudo  MINERVA  que  a  prevenção  de  pacing  auricular  e  antitaquicar-
dia (DDDRP),  em  combinação  com  algoritmos  de  redução  de  pacing  ventricular  (MVP),  reduzem
a  fibrilhação  auricular  (FA)  permanente  em  doentes  com  bradicardia,  com  FA  permanente  ou
paroxística  que  necessitam  de  pacing  cardíaco,  quando  comparado  com  a  estimulação  elétrica
de  dupla  câmara  (DDDR).  De  igual  forma,  a  utilização  de  recursos  hospitalares  foi  significativa-
mente  menor  no  grupo  DDDRP+MVP  comparativamente  ao  grupo  de  controlo.
Objetivo: Calcular  as  poupanças  associadas  à  menor  utilização  de  recursos  hospitalares  em
Portugal com  a  utilização  deste  novo  algoritmo.
Métodos:  O  impacto  nos  custos  foi  estimado  considerando  o  preço definido  para  a  hospitalização
associada à  FA,  o  custo  da  urgência  e  das  consultas  em  Portugal.
Resultados:  Foi  estimada  uma  redução  de  42%  na  utilização  de  recursos  hospitalares  com  o
novo algoritmo.  Em  Portugal,  este  resultado  representa  uma  poupança de  2.323D  por  cada  100
doentes  no  primeiro  ano  de  utilização  e  um  total  de  17.118D  ao  final  de  dez  anos.  Considerando
o número  de  doentes  que  podem  beneficiar  deste  algoritmo,  existe  um  potencial  de  poupança
de 75.369D  por  ano  e  de  555.410D  em  dez  anos.  Estas  poupanças  poderão  ser  superiores  se
forem  considerados  os  custos  de  hospitalização  decorrentes  da  insuficiência  cardíaca  e  AVC.
Conclusão:  A  combinação  de  prevenção  de  pacing  auricular  e  antitaquicardia  e  algoritmos  de
redução de  pacing  ventricular  reduzem  a  FA  permanente  ou  recorrente.  Estes  novos  algorit-
mos  de  pacing  podem  contribuir  de  forma  significativa  para  a  redução  dos  custos  hospitalares
relacionados  com  FA  em  Portugal.
© 2018  Sociedade  Portuguesa  de  Cardiologia.  Publicado  por  Elsevier  España,  S.L.U.  Este  é  um


























trial  fibrillation  (AF)  is  the  most  common  sustained  cardiac
rrhythmia encountered  in  clinical  practice.  Paroxysmal
nd persistent  AF  affect  about  2.2  million  individuals  in
orth America  and  4.5  million  in  the  European  Union.1,2 In
ortugal, the  prevalence  of  AF  is  estimated  at  2.5%  in  indi-
iduals aged  over  40  years  but  is  higher  in  older  age  groups:
% in  those  aged  over  65  and  10.4%  in  those  aged  over
0 years.  The  condition  is  not  identified  in  around  36%  of
hese patients.3,4 Gender  differences  are  not  significant.3
Since  AF  occurs  more  frequently  with  age,  a  significant
ise in  the  incidence  of  patients  suffering  from  the  condition
s expected  as  populations  age.5,6
AF  is  especially  common  among  bradycardia  patients,  one





F  at  pacemaker  implantation  or  during  follow-up.7,8 It  is
stimated that  1  million  pacemakers  were  implanted  in  2009
orldwide, meaning  that  more  than  333  000  individuals  with
acemakers may  suffer  from  AF.9
AF  accounts  for  approximately  one  third  of  hospital-
zations due  to  cardiac  rhythm  disturbances,  with  a  clear
pward trend  worldwide.  Data  from  the  USA  demonstrate
hat hospitalization  rates  increased  by  23%  in  patients  with
F from  2000  to  2010,  particularly  in  the  elderly.10 AF  also
ncreases the  risk  of  stroke  and  heart  failure.11,12
A  new  pacemaker  algorithm  that  includes  managed  ven-
ricular pacing  (MVP)  and  atrial  preventive  pacing  and  atrial
ntitachycardia pacing  (DDDRP)  has  been  developed  to
inimize the  detrimental  effect  of  right  ventricular  pacing,
ith the  aim  of  reducing  AF  and  related  health  care  costs.
he international  MINERVA  (MINimizE  Right  Ventricular
radycardia  patients  975
Table  1  Available  data  for  the  estimation  of  costs  of  atrial
fibrillation-related  health  care  services  in  Portugal.
Hospital  admissions
Type of  data  Tariff
Code  used  to  estimate  costs  of
AF-related  hospitalization
DRG  for  arrhythmia
Specific  to  patients  with  IPG? No
ED visits
Type  of  data Hospital  cost
Specific  to  AF/arrhythmia None
Specific to  patients  with  IPG?  No
Separate  cost  for  ED  visit  when
subsequently admitted?
No
Unscheduled  outpatient  visits
Type  of  data  Hospital  cost
Specific  to  AF/arrhythmia  None































Health  care  cost  analysis  of  enhanced  pacing  modalities  in  b
pacing  to  prevent  Atrial  fibrillation  and  heart  failure)  trial13
established  that  the  DDDRP  +  MVP  pacing  modality  reduces
AF. The  incidence  of  permanent  AF  was  considerably  lower
(61% risk  reduction)  in  bradycardia  patients  with  the  new
pacing algorithm  than  in  those  with  standard  dual-chamber
pacing (DDDR).13 AF-related  hospitalizations  and  emergency
department (ED)  visits  also  fell  as  a  consequence.
Following  the  MINERVA  trial,  a  cost-analysis  study  in  2015
by Boriani  et  al.14 estimated  the  health  care  cost  savings
achievable by  reductions  in  AF-related  hospitalizations  and
ED visits  for  the  USA,  Italy,  Spain  and  the  UK.  The  purpose  of
the present  study  was  to  estimate  current  and  future  savings
arising from  this  new  algorithm  for  the  Portuguese  health
care system,  using  the  same  cost-analysis  methodology  as  in
Boriani et  al.
Methods
Study  design  and  patient  population
MINERVA  was  a  prospective,  multicenter,  randomized,
single-blind, controlled  trial  with  an  international  scope
involving 63  cardiology  centers  in  15  countries  enrolling
1166 patients.13,15
The  inclusion  criteria  were  standard  class  I  or  II  indication
for dual  chamber  pacing  and  a  history  of  at  least  one  docu-
mented episode  of  AF,  atrial  flutter  or  atrial  tachycardia  in
the last  12  months.
The  objective  of  the  MINERVA  trial  was  to  compare  stan-
dard DDDR  pacing  with  the  DDDRP  +  MVP  combination.
Economic  analysis  and  health  care  costs  in  Portugal
The  aim  of  Boriani  et  al.’s  study14 was  to  compare  health
care costs  in  two  groups:  DDDRP  +  MVP  and  DDDR  (con-
trols). Three  different  health  care  services  were  included
in the  MINERVA  trial:  AF-related  hospitalizations,  ED  visits,
and outpatient  visits,  the  latter  defined  as  follow-up  visits
that were  not  mandatory  in  the  study.  The  costs  related  to
these services  were  not  collected  in  the  MINERVA  trial;  the
cost analysis  was  performed  taking  into  account  the  num-
ber of  health  care  services  that  were  avoided  with  DDDRP  +
MVP and  an  average  cost  associated  with  each  health  care
service.
The methods  for  estimating  costs  differ  from  country  to
country depending  on  the  availability  of  data.  Actual  hospi-
tal costs  were  available  in  the  USA,  while  diagnosis-related
group (DRG)  tariffs  (Spain,  Italy,  Portugal)  or  DRG  reference
costs (UK)  were  used  for  European  countries.  Moreover,
although in  the  USA  costs  can  be  differentiated  for  patients
with an  implanted  pacemaker,  this  is  not  the  case  in  the
European countries  under  analysis.  The  methods  used  to
estimate Portuguese  costs  are  summarized  in  Table  1.
Specific  AF-related  hospitalization  costs  are  not  available
at hospital  level  in  Portugal.  Therefore,  hospitalization  costs
were estimated  on  the  basis  of  DRG  tariffs,  as  in  Boriani
et al.14 for  the  UK,  Italy  and  Spain.As  in  Spain,  Portuguese  hospitals  have  overall  budgets
that are  linked  to  DRGs.  DRG  tariffs  are  the  established
price for  treating  patients  outside  the  coverage  area  and




AF: atrial fibrillation; DRG: diagnosis-related group; ED: emer-
gency  department; IPG: implanted pulse generator.
pecific  diseases  or  procedures.  The  tariffs  are  published  by
he Central  Administration  of  the  National  Health  System
ACSS).16
Since  different  DRGs  are  available  (for  ablation  and
rrhythmia) and  vary  according  to  different  levels  of
everity,16 a weighted  average  for  the  cost  of  hospitalization
as estimated  as  in  Boriani  et  al.14 Regarding  DRG  choice,  it
as considered  that  4.5%  of  patients  are  coded  for  ablation
all-patient refined  [APR]-DRG  175,  percutaneous  cardiovas-
ular procedures  without  acute  myocardial  infarction)  and
he other  95.5%  are  coded  as  APR-DRG  201  (cardiac  arrhyth-
ia and  conduction  disorders).  These  percentages  are  based
n the  number  of  patients  who  underwent  ablation  in  the
INERVA trial.13
For  the  choice  of  level  of  severity,  MINERVA  showed  that
0% of  these  hospital  admissions  have  complications.  For  this
eason, in  this  analysis  it  was  considered  that  20%  of  hospital
dmissions are  classified  as  severity  level  3  to  accommo-
ate possible  complications  and  the  other  80%  of  hospital
dmissions were  considered  severity  level  1.
The  costs  of  ED  and  outpatient  visits  were  collected  from
n ACSS  database  recording  costs  of  various  activities  of  hos-
itals in  the  Portuguese  National  Health  System.17 In  both
ases the  average  cost  was  considered.  These  costs  are  not
pecific to  AF-related  visits;  for  outpatient  visits  the  average
ost of  cardiology  outpatient  visits  was  used.
The  average  cost  for  each  service  (hospitalization,  ED
isit and  outpatient  visit)  in  Portugal  is  presented  in  Table  2.
he cost  of  the  event  was  assumed  to  be  independent  of  the
acing modality  and  thus  only  the  frequency  of  visits  varied.
To  estimate  the  savings  from  the  DDDRP  +  MVP  pacing
lgorithm, the  same  methodology  as  in  Boriani  et  al.14 was
sed: the  number  of  events  reported  was  estimated  as  event
ates per  100  patients  and  the  costs  per  event  were  mul-
iplied by  the  event  rate,  giving  the  costs  of  AF-related
ospitalizations for  both  groups.  The  difference  between  the
roups represents  the  cost  savings  per  year  (Figure  1).
The  cost  savings  over  a  10-year  period  were  calculated  to
eflect the  total  saving  over  the  lifetime  of  the  device.  Event
976  
Table  2  Tariffs  and  provider  costs  of  atrial  fibrillation-
related health  care  services  in  Portugal  (values  in  euros).
Hospitalization  (a)  1175.92
Arrhythmia  --  APR-DRG  201
Severity level  1  776.44
Severity  level  2  1231.62
Severity  level  3  2169.61
Severity  level  4  5233.34
Ablation  --  APR-DRG  175
Severity level  1 2103.80
Severity level  2 2770.33
Severity level  3 5012.60
Severity level  4  11  435.74
Emergency  visits  150.34
Outpatient  visits  110.22
APR-DRG 201: cardiac arrhythmia and conduction disorders;
APR-DRG 175: percutaneous cardiovascular procedures without
acute  myocardial infarction.
Weighted  average assuming 4.5% of hospitalizations are coded as
DRG  175 (the other 95.5% are coded as DRG 201) and that 80% of
hospitalizations are classified as severity level 1 while the other
20%  are classified as severity level 3.















































emergency visits and outpatient visits: average cost from
ACSS.17
ates  were  assumed  to  be  constant  over  the  device’s  life-
ime. As  AF  is  a  progressive  disease,  it  is  unlikely  to  improve
uring a  longer  follow-up  period  and  the  frequency  of  hospi-
al care  is  thus  unlikely  to  fall.  The  discount  rate  considered
as 5%  per  year,  which  is  the  discount  rate  suggested  by  the
ortuguese methodological  guidelines.18 A  mortality  rate  of
.3% was  assumed,  in  line  with  the  MINERVA  trial  results.13
An  additional  analysis  was  performed  considering  the
otal number  of  patients  who  could  benefit  from  this  pac-
ng modality  in  Portugal.  According  to  the  White  Book  of
he European  Heart  Rhythm  Association,  in  2014  there  were
830 pacemakers  implanted  in  Portugal.19 The  European
ociety of  Cardiology  attributes  36%  of  pacing  indications
o AF  plus  atrioventricular  block  and  sinus  node  dysfunc-

















Cost of events in
DDDR group
×r c
Figure  1  Scheme  of  coJ.  de  Sousa  et  al.
rom  the  DDDRP  +  MVP  pacing  modality.20 This  suggests  that
179 patients  per  year  in  Portugal  could  benefit  from  the
ew pacing  algorithm.
esults
n  the  MINERVA  trial  (Table  3),  the  383  patients  assigned  to
he DDDRP  +  MVP  pacing  modality  had  a  significantly  reduced
vent rate,  and  42%  fewer  AF-related  hospitalizations  and
8% fewer  ED  visits,  compared  to  the  385  patients  in  the
ontrol group  (DDDR).13 The  difference  in  outpatient  visits
etween the  two  groups  was  not  significant.  Table  3  reports
he results  of  the  MINERVA  trial.
Costs  were  calculated  for  each  group  as  the  event  rates
eported multiplied  by  the  respective  costs.  Table  4  presents
he costs  per  year  for  each  group  and  savings  (the  difference
n costs  between  the  two  groups).
Opting  for  the  DDDRP  +  MVP  pacing  algorithm  results  in
avings of  2371  euros  per  100  patients  per  year  and  17  471
uros over  a  10-year  period.  The  MINERVA  pacing  algorithm
ould reduce  health  care  costs  in  this  patient  group  in  Por-
ugal by  41%.  The  sensitivity  analysis  (Table  5)  presents
onfidence intervals  for  the  cost  savings  estimated  using  the
onfidence intervals  of  event  rates.  The  lower  bounds  still
epresent a  reduction  of  19%  in  health  care  utilization  costs.
Considering  the  number  of  patients  who  could  poten-
ially benefit  from  this  pacing  modality  each  year  --  around
179 patients  -- Portugal could  save  75  369  euros  a  year.
hese same  3179  patients  would  represent  savings  of  around
55 410  euros  by  the  end  of  a  10-year  period  (Table  6).
iscussion
he  benefits  of  the  DDDRP  +  MVP  algorithm  were  established
n the  MINERVA  trial.  In  Portugal,  these  benefits  represent  a
otential cost  saving  of  2371  euros  per  100  patients  in  the
rst year  and  17  471  euros  over  a  10-year  period,  and  a  total
f 75  369  euros  per  year  and  555  410  euros  over  10  years  if
ll potential  patients  were  considered.Compared  to  the  estimated  cost  savings  for  other  coun-
ries in  Boriani  et  al.,14 the  savings  for  Portugal  are
ubstantially lower.  Two  main  factors  contribute  to  this  dif-







Cost of events in
DDDRP + MVP group 
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st-saving  analysis.
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Table  3  Health  care  event  rates  stratified  by  group  in  the  MINERVA  trial.
Event  rate  per  100  patients  per  year  IRR  Difference  Reduction  p
DDDR  (controls)  DDDRP  +  MVP
Hospitalization  4.3  (3.0  to  6.1)  2.5  (1.5  to  4.0)  0.58a 1.8  (1.0  to  3.2)  42%  0.003
ED  visit  2.7  (1.7  to  4.2)  0.9  (0.4  to  1.9)  0.32a 1.8  (0.9  to  3.2)  68%  <0.001
Outpatient  visit  2.4  (1.5  to  3.9)  2.9  (1.8  to  4.5)  1.2  −0.5(−1.3  to  0.1)  NS  0.310
DDDR: dual-chamber pacing; DDDRP: atrial preventive pacing and atrial antitachycardia pacing; ED: emergency department; IRR:
incidence rate ratio; MVP: manged ventricular pacing; NS: not significant.
a Significant at 1% p-value; 95% confidence interval reported for event rates and differences.
Table  4  Cost  savings  calculated  for  the  Portuguese  health  care  setting  (values  in  euros).
Average  tariff/
costs per  episode
Costs  per  100  patients  per  year  Cost  savings  per  100  patients
DDDR  (controls)  DDDRP  +  MVP  Per  year  10-year  period
AF-related
hospitalization
1176 5056  2905  2152  15  858
AF-related  ED  visit  150  406  131  275  2027
Outpatient  visit  110  265  321  −56  −414
Total  5727  3356  2371  17  471
AF: atrial fibrillation; DDDR: dual-chamber pacing; DDDRP: atrial preventive pacing and atrial antitachycardia pacing; ED: emergency
department; MVP: managed ventricular pacing.
Table  5  Sensitivity  analysis  of  cost  savings  for  Portugal  (values  in  euros).
Per  year  95%  CI  10-year  period  95%  CI
Lower  bound  Upper  bound  Lower  bound  Upper  bound
AF-related  hospitalization  2152  1764  2469  15  858  15  470  16  176
AF-related ED  visit  275  195  346  2027  1948  2098
Outpatient  visit  −56  −33  −66  −414  −391  −424
Total 2371  1926  2749  17  471  17  027  17  849
artment.
Table  6  Cost  savings  for  Portugal  (values  in  euros).
Per  year  10-year
period








AF: atrial fibrillation; CI: confidence interval; ED: emergency dep
a  conservative  approach  was  taken  regarding  the  costs  of
hospitalizations and  ablation.  It  was  assumed  that  80%  of
hospital admissions  were  not  severe,  and  were  therefore
classified as  the  lowest  severity  level  (out  of  4).  The  20%
of hospital  admissions  with  complications  were  considered
to be  classified  as  severity  level  3.  This  represents  the  low-
est cost-saving  scenario,  meaning  that  the  savings  could
potentially be  higher.  Moreover,  the  Portuguese  methodolog-
ical guidelines  for  health  care  cost  analysis  suggest  the  use
of a  5%  discount  rate,  which  is  a  more  conservative  rate
than that  used  by  Boriani  et  al.14 (3.5%).  Using  a  lower  dis-
count rate  would  lead  to  higher  cost  savings  over  a  10-year
period.
The cost-saving  analysis  only  took  AF-related  hospital-
izations into  account.  Optimization  of  the  algorithm  could,
however, potentially  reduce  other  hospitalizations  related
to heart  failure  and  stroke.  This  also  means  that  savings
could be  higher  than  those  estimated  in  this  analysis.
A  data  collection  limitation  arises  directly  from  the  MIN-




Total cost  savings  (3179  patients)  75  369  555  410
ata  were  collected,  on  which  the  trial’s  results  depend.
he benefits  of  the  algorithm  are  applicable  to  the  lifetime
f the  device  and  thus  differences  in  the  number  of  hospital
dmissions and  ED  visits  are  expected  to  remain  at  least  the
ame between  the  treatment  and  control  groups.
As  this  cost-savings  analysis  focuses  on  reduction  of
ealth care  utilization,  the  price  difference  of  devices
ith the  new  algorithm  was  not  taken  into  consideration.
his study  was  not  intended  to  analyze  the  relative  cost-
ffectiveness of  devices  but  to  determine  the  potential  of





































lines on cardiac pacing and cardiac resynchronization therapy:78  
haracteristics  of  the  medical  devices  market,  in  which
rices tend  to  decline  and  converge.  In  this  context,  any
nalysis in  which  assumptions  are  made  about  pricing  is
iable to  become  rapidly  outdated.
onclusion
he  combination  of  atrial  preventive  pacing,  a  new  gener-
tion of  atrial  antitachycardia  pacing,  and  an  algorithm  to
inimize the  detrimental  effect  of  right  ventricular  pacing
educes recurrent  and  permanent  AF.  This  results  in  a  fall  in
F-related health  care  utilizations.  The  new  DDDRP  +  MVP
acing mode  could  contribute  to  significant  costs  savings  in
he Portuguese  health  care  setting.
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